首页> 美国卫生研究院文献>Clinical and Molecular Hepatology >Effects of candesartan and propranolol combination therapy versus propranolol monotherapy in reducing portal hypertension

【2h】

Effects of candesartan and propranolol combination therapy versus propranolol monotherapy in reducing portal hypertension

机译：坎地沙坦和普萘洛尔联合治疗与普萘洛尔单药治疗在降低门脉高压中的作用

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background/AimsAngiotensin receptor blockers (ARBs) inhibit activated hepatic stellate cell contraction and are thought to reduce the dynamic portion of intrahepatic resistance. This study compared the effects of combined treatment using the ARB candesartan and propranolol versus propranolol monotherapy on portal pressure in patients with cirrhosis in a prospective, randomized controlled trial.

机译：背景/目的血管紧张素受体阻滞剂（ARBs）抑制活化的肝星状细胞收缩，并被认为可降低肝内耐药性的动态部分。这项研究在一项前瞻性，随机对照试验中比较了使用ARB坎地沙坦和普萘洛尔与普萘洛尔单药联合治疗对肝硬化患者门脉压力的影响。

著录项

期刊名称 Clinical and Molecular Hepatology
作者
Jae Hyun Kim; Jung Min Kim; Youn Zoo Cho; Ji Hoon Na; Hyun Sik Kim; Hyoun A Kim; Hye Won Kang; Soon Koo Baik; Sang Ok Kwon; Seung Hwan Cha; Young Ju Kim; Moon Young Kim;
展开▼
作者单位

展开▼
年(卷),期 2014(20),4
年度 2014
页码 376–383
总页数 8
原文格式 PDF
正文语种
中图分类分子生物学;
关键词
Portal hypertension Angiotensin receptor blocker Non-selective beta blocker Cirrhosis Hepatic venous pressure gradient;

机译：门脉高压;血管紧张素受体阻滞剂;非选择性β阻滞剂;肝硬化;肝静脉压力梯度;

相似文献

外文文献
中文文献
专利

1. Rifaximin and Propranolol Combination Therapy Is More Effective than Propranolol Monotherapy for the Reduction of Portal Pressure: An Open Randomized Controlled Pilot Study [J] . Yoo Li Lim, Moon Young Kim, Yoon Ok Jang, Gut and Liver . 2017,第5期

机译：利福昔明和普萘洛尔联合疗法比普萘洛尔单药疗法更有效降低门静脉压力：一项开放随机对照试验研究
2. Evaluation of the Efficacy and Tolerability of Combination Therapy With Candesartan Cilexetil and Amlodipine Besilate Compared With Candesartan Cilexetil Monotherapy and Amlodipine Besilate Monotherapy in Japanese Patients With Mild-to-Moderate Essential Hypertension: A Multicenter, 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study [J] . RakugiH., OgiharaT., MiyataY., Clinical therapeutics . 2012,第4期

机译：日本轻度至中度原发性高血压患者与Candesartan Cilexetil和苯磺酸氨氯地平联合疗法与Candesartan Cilexetil单一疗法和Amlodipine苯磺酸盐联合疗法的疗效和耐受性评估：多中心，12周，随机，双盲，安慰剂控制的平行小组研究
3. Efficacy and Tolerability of Combination Therapy Versus Monotherapy with Candesartan and/or Amlodipine for Dose Finding in Essential Hypertension: A Phase II Multicenter, Randomized, Double-blind Clinical Trial [J] . Sohn Il Suk, Kim Chong-Jin, Ahn Taehoon, Clinical therapeutics . 2017,第8期

机译：组合治疗与单药治疗的疗效和含量与坎莎坦和/或氨氯肽剂的疗效和/或氨基氨基对必需高血压的剂量发现：II期多中心，随机，双盲临床试验
4. Superior effects of Losartan to propranolol on opening angle of portal vein of carbon tetrachloride- induced portal hypertension rats~△ [C] . Zong-Qi Zhang, Bin Shi, Su Liu, World congress on medical physics and biomedical engineering;International congress of the IUPESM . 2011

机译：氯沙坦/普萘洛尔对四氯化碳所致门静脉高压症大鼠门静脉张开角的改善作用〜△
5. The evaluation of anti-cancer effects of FL118 in retinoblastoma in monotherapy and combination therapies. [D] . Singh, Jasman Kaur. 2014

机译：在单一疗法和联合疗法中评估FL118在视网膜母细胞瘤中的抗癌作用。
6. Rifaximin and Propranolol Combination Therapy Is More Effective than Propranolol Monotherapy for the Reduction of Portal Pressure: An Open Randomized Controlled Pilot Study [O] . Yoo Li Lim, Moon Young Kim, Yoon Ok Jang, 2017

机译：利福昔明和普萘洛尔联合疗法比普萘洛尔单药疗法更有效降低门静脉压力：一项开放随机对照试验研究
7. Effects of candesartan and propranolol combination therapy versus propranolol monotherapy in reducing portal hypertension [O] . Jae Hyun Kim, Jung Min Kim, Youn Zoo Cho, 2014

机译：坎地沙坦和普萘洛尔联合治疗与普萘洛尔单药治疗降低门静脉高压的疗效比较

Effects of candesartan and propranolol combination therapy versus propranolol monotherapy in reducing portal hypertension

摘要

著录项

相似文献

相关主题

期刊订阅